Sophiris Bio

Micrograph showing the most common prostate cancer
Biotech

Sophiris slides on prostate cancer data but vows to press on

Sophiris will push its lead drug topsalysin into phase 3 testing, though a second dose showed no additional benefit in its prostate cancer trial.
Phil Taylor Dec 18, 2018 9:53am
rocket launch

Sophiris clears its lead drug following patient death in study

Aug 30, 2018 7:37am
stop sign knerri61Pixabay

Sophiris cuts second dose in topsalysin trial after patient dies

Jun 25, 2018 10:06am